Cisplatin is a widely used cancer chemotherapeutic that promotes DNA damage-associated apoptosis. Although platinum compounds are known to form DNA adducts and provoke DNA damage, the molecular mechanism of cisplatin-induced cell death remains unclear. In this article, we show that the BH3-only protein Noxa is strongly transcriptionally upregulated in response to cisplatin and related platinum compounds. Cisplatininduced Noxa expression was ERK dependent, but p53 independent, and inhibition of ERK activation markedly attenuated cisplatin-induced cell death, as well as Noxa expression. Furthermore, siRNA-mediated ablation of Noxa expression also inhibited cisplatin-induced cell death and permitted clonogenic survival. These observations reveal a novel ERK-regulated route to Noxa expression that is important for the cell killing activity of platinumbased chemotherapeutic drugs.
Introduction
Apoptosis is a regulated mode of cell death that is invoked during development and tissue homeostasis, as well as in response to cell injury or infection (Taylor et al., 2008) . Numerous chemotherapeutic drugs also exert their cell killing effects by invoking apoptosis (Martin and Cotter, 1990; Lennon et al., 1991; Martin and Green, 1994) , although precisely how these agents trigger activation of the cell death machinery is in many cases still unknown. Innate or acquired resistance to chemotherapy is a major cause of treatment failure in cancer patients. However, to understand the mechanisms of drug resistance to therapy, it is important to know how cytotoxic chemotherapeutic agents kill cells in the first instance.
Cisplatin is effective in the treatment of several malignancies and is particularly effective against testicular and ovarian cancer (Siddik, 2003; Wang and Lippard, 2005) . Cisplatin is thought to kill primarily through inducing DNA damage but the major DNA damage response regulator, p53, is not essential for cisplatin-induced cell death (Gong et al., 1999; Petit et al., 2003) . Although activation of the ERK/MAPK pathway is typically associated with signals that result in cell proliferation, survival and differentiation (Kolch, 2005) , several previous studies have implicated the MEK/ERK pathway as a positive regulator of cisplatin-associated cytotoxicity, but the precise role of ERK in promoting cell death remains unclear (Wang et al., 2000; Schweyer et al., 2004; Amran et al., 2005) .
Much evidence now argues that the 'BH3-only' proteins, a subset of the Bcl-2 family, are major sentinels of cell stress or damage that are frequently transcriptionally upregulated or post-translationally stabilized in response to such stimuli (Willis and Adams, 2005; Labi et al., 2006) . On activation, BH3-only proteins promote cell death by opening the mitochondrial Bax/Bak channel, thereby initiating the apoptosome pathway to apoptosis (Adrain and Martin, 2006) . BH3-only protein-initiated Bax/Bak channel opening is achieved through a combination of direct binding of BH3-only proteins to Bax and/or Bak (Kuwana et al., 2005; Kim et al., 2009) , and also through neutralizing interactions between BH3-only proteins and antiapoptotic Bcl-2 family members (Cheng et al., 2001) . The sum of the latter actions promotes conformational changes in Bax and/or Bak that permit their oligomerization within the mitochondrial outer membrane and formation of a pore that permits the release of cytochrome c into the cytoplasm. Cytoplasmic cytochrome c functions as a cofactor for assembly of the Apaf-1/caspase-9 apoptosome, thereby initiating the caspase activation cascade that culminates in apoptosis (Slee et al., 1999; Taylor et al., 2008) .
Noxa is a BH3-only protein that has been previously implicated in apoptosis associated with DNA damage, hypoxia or exposure to inhibitors of the proteasome (Shibue et al., 2003; Villunger et al., 2003; Kim et al., 2004; Fernandez et al., 2005; Qin et al., 2005) . Apoptosis-associated Noxa activation is primarily achieved through transcriptional upregulation, and a number of transcription factors including p53, Hif-1a and Myc have been implicated in the regulation of Noxa expression (Oda et al., 2000; Kim et al., 2004; Nikiforov et al., 2007) . Noxa preferentially binds to the antiapoptotic Bcl-2 family members Mcl-1 and A1, and this BH3-only protein appears to be a critical mediator of apoptosis in cells showing a dependency on Mcl-1 expression (Alves et al., 2006) .
To address how cisplatin activates the cell death machinery, we explored whether cisplatin-induced apoptosis was associated with upregulation of one or more members of the BH3-only family. We observed a dramatic increase in Noxa expression in response to treatment with cisplatin, as well as the related compounds carboplatinum and oxaliplatinum. Upregulation of Noxa in this context was ERK dependent and inhibition of the ERK pathway blocked cisplatin-induced cell death. RNA interference-mediated ablation of Noxa expression also dramatically attenuated cisplatin-mediated cell death and permitted long-term clonogenic survival. These observations reveal a novel ERKregulated route to Noxa expression that is important for the cell killing activity of platinum-based chemotherapeutic drugs.
Results
Noxa is transcriptionally upregulated in response to cisplatin treatment Human cervical carcinoma HeLa cells undergo apoptosis in response to many cytotoxic drugs, including cisplatin ( Figure 1a ). Although untreated HeLa cells express barely detectable amounts of Noxa, this BH3-only protein was strongly and selectively upregulated in response to cisplatin treatment (Figure 1b) . In contrast, Puma, Bim, Bad and Bid levels either decreased or were unchanged in response to cisplatin. We also treated HeLa cells with the proteasome inhibitor, MG132, as previous studies have shown that proteasome inhibition leads to increased levels of Noxa, most likely through decreased turnover of this protein in addition to transcriptional upregulation Qin et al., 2005) . As expected, Noxa expression levels were also strongly increased in the presence of MG132 (Figure 1b) , as was Mcl-1, a protein also known to undergo degradation through the proteasome (Nijhawan et al., 2003) . However, cisplatin-induced Noxa ERK-induced Noxa upregulation and apoptosis C Sheridan et al expression was not accompanied by increases in Mcl-1 levels, suggesting that the mechanisms of MG132 and cisplatin-associated Noxa induction were distinct.
We also observed identical results with the human melanoma cell line, SK-MEL-3, where increased amounts of Noxa were observed after cisplatin treatment, again in the absence of Mcl-1 stabilization (Figures 1c and d) . Similar to our observations in HeLa cells, MG132 treatment of SK-MEL-3 cells resulted in stabilization of both Noxa and Mcl-1 (Figures 1c and d) .
Increases in Noxa expression levels in response to cisplatin treatment were evident over a wide range of cisplatin concentrations and occurred within 5 h of drug treatment (Figures 1e and f) . Interestingly, cisplatininduced expression of Noxa also correlated with ERK activation in response to the same treatment (Figures 1e  and f) . We next explored whether upregulation of Noxa was a transcriptional or post-translational response to cisplatin, by treating HeLa cells with this drug in the presence or absence of the translational inhibitor, cycloheximide (CHX). As Figure 1g illustrates, CHX treatment completely blocked cisplatin-induced Noxa upregulation, strongly suggesting that the cisplatininduced increase in Noxa expression levels reflected a transcriptional response. Furthermore, the rate of Noxa degradation was unaltered in the presence or absence of cisplatin, indicating that cisplatin promotes upregulation of Noxa on a transcriptional level, rather than enhancing Noxa stability (Figure 1h ).
Cisplatin-induced upregulation of Noxa and apoptosis are ERK dependent Previous reports have shown that cisplatin-induced cell death is associated with ERK activation and can be attenuated by inhibitors of the upstream ERK kinase, MEK (Wang et al., 2000; Schweyer et al., 2004; Amran et al., 2005) . Consistent with these reports, we observed rapid ERK activation (as indicated by the detection of phosphorylated ERK) over a wide range of cisplatin concentrations (Figures 1e-g ). Thus, we explored whether cisplatin-induced expression of Noxa was ERK dependent. As Figures 2a and b illustrate, cisplatin-induced apoptosis of HeLa cells was greatly attenuated by co-incubation with the MEK inhibitor, U0126. Importantly, cisplatin-induced Noxa expression was also suppressed by inhibition of MEK/ERK activation ( Figure 2c ). Interestingly, cisplatin treatment also led to degradation of Bim, Mcl-1 and Bcl-xL, which was also inhibited by U0126 (Figure 2c ).
MEK/ERK pathway inhibition did not merely delay cell death in response to cisplatin treatment but also afforded long-term protection, as assessed by colony formation assays (Figure 2d ). In contrast, apoptosis induced by several other proapoptotic stimuli, including MG132, remained unaffected by the same inhibitor ( Figure 2e ). It was also evident that whereas cisplatin treatment was clearly associated with increased ERK activation, as indicated by increased detection of phospho-ERK, MG132 treatment was not associated with enhanced ERK activation (Figure 2f) . Thus, the mechanism of Noxa upregulation in response to cisplatin is distinct from that observed in response to inhibition of proteasome activity.
To further confirm the role of ERK in cisplatininduced cell death, we used other ERK pathway inhibitors, PD98059 and ERK Inhibitor peptide II. These inhibitors also attenuated cisplatin-induced apoptosis (Figure 3a) , as well as cisplatin-induced Noxa expression and caspase-3 activation (Figure 3b ). Furthermore, cisplatin-induced apoptosis of H460 nonsmall-cell lung cancer cells (Figures 4a and b ) and HT29 colon cancer cells (Figures 4d and e) was similarly attenuated by inhibition of ERK. Once again, cisplatin treatment of both cell types also resulted in greatly increased Noxa expression, which was also ERK dependent (Figures 4c and f) . Collectively, these data argue that ERK has an influential role in cisplatin-mediated Noxa upregulation and apoptosis in a diverse range of cell types.
Cisplatin-induced upregulation of Noxa is p53 independent
Previous studies have implicated the p53 tumor suppressor as a major regulator of Noxa expression (Oda et al., 2000) . To explore whether Noxa induction was p53 dependent in the context of cisplatin treatment, we used the p53-null cell line HL-60 (Wolf and Rotter, 1985) . We first verified that these cells do not express p53, either constitutively or in response to DNA-damaging agents, such as cisplatin or etoposide ( Figure 5a ). As Figure 5b shows, HL-60 cells underwent apoptosis in response to cisplatin and, once again, this was associated with a strong and selective induction of Noxa, but not of any other BH3-only protein examined ( Figure 5c ). Furthermore, cisplatin-induced apoptosis in HL-60 cells was strongly attenuated in the presence of the MEK inhibitor, U0126, whereas apoptosis mediated by other proapoptotic drugs was unaffected (Figures 5d and e). Cisplatin-induced Noxa expression in HL-60 cells was also abolished by inhibition of the MEK/ERK pathway ( Figure 5f ). In addition, siRNA-mediated knockdown of p53 expression in HeLa cells did not modulate cisplatin-mediated Noxa upregulation or apoptosis (Supplementary Figure S1a) . These data argue that cisplatin-induced Noxa expression is ERK dependent but p53 independent.
Cisplatin analogues carboplatin and oxaliplatin upregulate Noxa and induce apoptosis in an ERK-dependent manner The cisplatin analogues carboplatin and oxaliplatin, both of which are widely used in cancer therapy, can also promote apoptosis in HeLa cells (Figures 6a and c) . We explored whether these compounds also provoked ERK-dependent upregulation of Noxa. As Figures 6b and d show, apoptosis induced by both platinum compounds was associated with increased ERK activation and Noxa expression. Furthermore, apoptosis induced by carboplatin and oxaliplatin treatment was also suppressed by inhibition of the MEK/ERK pathway ( Figure 6e ) and Noxa expression was strongly inhibited under the same conditions (Figure 6f ). Similar to cisplatin, carboplatin-and oxaliplatin-induced apoptosis and Noxa upregulation were also p53 independent, but ERK dependent, as indicated by experiments using HL-60 cells (Figures 6g and h ).
Noxa is upregulated in response to oncogene-driven ERK activation Ras and B-Raf are the most widely known proximal activators of the MEK/ERK pathway (Dhomen and Marais, 2007; Schubbert et al., 2007) . Because the preceding experiments suggested that cisplatin-induced Noxa expression was ERK dependent, we wondered whether Ras-or B-Raf-induced ERK activation was sufficient to induce expression of this BH3-only protein.
Thus, we transiently expressed a constitutively active Ras mutant, H-Ras V12G , into HeLa cells to explore whether Ras-induced ERK activation led to increased expression of Noxa. We also expressed a constitutively active form of the downstream Ras target, B-Raf ERK-induced Noxa upregulation and apoptosis C Sheridan et al strongly activated ERK and this was associated with a striking increase in the expression of Noxa. In contrast, a dominant-negative form of Ras, H-Ras
N17S
, and wildtype B-Raf, both of which failed to activate ERK, also failed to upregulate Noxa (Figures 7a and b) . Oncogenic Ras-and B-Raf-induced Noxa expression was inhibited by U0126, indicating that this effect was ERK dependent (Figure 7c) . Therefore, Noxa can be induced by ERK activation in multiple contexts. However, although oncogenic H-Ras and B-Raf increased Noxa expression in a similar manner to cisplatin, expression of these oncogenes was not sufficient to induce apoptosis within the same time frame as cisplatin treatment (Figure 7d ), despite producing similar levels of Noxa upregulation (Figure 7e ). This is most likely because, in addition to upregulating Noxa, Ras and B-Raf expression also impacts upon other components of the cell death machinery to suppress apoptosis. For example, we and others have previously shown that oncogenic Ras and B-Raf expression leads to phosphorylation and inactivation of the BH3-only proteins Bim and Bad (Ley et al., 2003; Sheridan et al., 2008) . In addition, Mcl-1 is also upregulated through Ras/B-Raf overexpression (Figure 7c) . Thus, the inactivation of Bad and Bim, coupled with increased expression of Mcl-1, most likely counterbalances the effects of Ras/B-Raf-induced Noxa upregulation.
Ablation of Noxa expression protects from cisplatin-mediated apoptosis Although cisplatin-induced apoptosis was associated with ERK-dependent induction of Noxa, it was clearly possible that Noxa expression merely correlated with apoptosis but was not essential for cell death in this context. To address this issue, we silenced Noxa expression using a panel of siRNAs targeted against the NOXA transcript and explored whether cisplatininduced cell death was affected. As Figure 8a illustrates, silencing of Noxa expression robustly inhibited apoptosis associated with cisplatin treatment, but had no effect on apoptosis induced by several other proapoptotic drugs (data not shown). Knockdown of Noxa also attenuated oxaliplatin-and carboplatin-mediated apoptosis (Figure 8b) . Importantly, the protection from cisplatin-induced cell death observed when Noxa expression was silenced was long term, as indicated by colony formation assays (Figure 8c ). In contrast, silencing of the BH3-only proteins Bad and Bim had no effect on cisplatin-induced cytotoxicity (Figures 8d  and e) . However, shRNA-mediated ablation of both Bax and Bak also provided effective protection against cisplatin-mediated apoptosis, confirming that cisplatin promotes Noxa expression and apoptosis in a Bax/ Bak-dependent manner (Figure 8e ).
Reduced Mcl-1 expression sensitizes to cisplatin treatment Noxa selectively binds to the antiapoptotic Bcl-2 family members Mcl-1 and A1 (Chen et al., 2005; Alves et al., 2006) . However, because A1 has a very restricted pattern of expression, Mcl-1 is the most commonly expressed inhibitor of Noxa in tumor cells (Choi et al., 1995) . Thus, we also examined the effects of modulating Mcl-1 expression on cisplatin-induced apoptosis. Overexpression of Mcl-1 dramatically inhibited cisplatin-mediated cell death, even in the presence of high concentrations of this drug (Figure 9a ). Immunoprecipitation of overexpressed Mcl-1 from cells treated with cisplatin revealed that Mcl-1 captured cisplatinupregulated Noxa, thus inhibiting Noxa-mediated apoptosis (Figure 9b) .
We also explored the effects of silencing Mcl-1 expression on sensitivity to cisplatin treatment. Whereas, shRNA-mediated silencing of Noxa expression afforded greatly increased protection against cisplatin, shRNA-mediated silencing of Mcl-1 sensitized cells to this drug (Figure 9c) . Furthermore, ablation of Mcl-1 expression using two siRNAs similarly enhanced cisplatin-induced apoptosis (Figure 9d) . Interestingly, when we simultaneously silenced Noxa and Mcl-1, the protection from cisplatin-induced apoptosis observed through silencing of Noxa expression was somewhat reversed, again suggesting that the Noxa/Mcl-1 axis has a major effect on the sensitivity to cisplatin-associated cytotoxicity (Figure 9e) . Thus, Noxa and Mcl-1 are 
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C Sheridan et al critical determinants of cisplatin-mediated cell death and the balance between these proteins may influence the effectiveness of cisplatin-based therapy.
Discussion
Here we have shown that the BH3-only protein Noxa is an important effector of apoptosis in response to cisplatin and related DNA damage-inducing compounds. Platinum-induced Noxa expression was positively regulated by the ERK/MAPK pathway and was p53 independent. Previous studies have linked ERK activation to cell survival through inactivation of the BH3-only proteins Bim and Bad (Ley et al., 2003; Sheridan et al., 2008) . However, here we show that hyperactivation of ERK in response to platinum compounds results in apoptosis, suggesting that ERK 
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has a dual role in cell death control, depending on the context. Importantly, we have also shown that silencing of Noxa mRNA expression provided cells with long-term protection against platinum compounds. In contrast, silencing of other BH3-only proteins had no effect in this context.
Cisplatin therapy is effective for the treatment of many cancer types including testicular cancer, non-small-cell lung cancer, head and neck cancers, advanced cervical carcinomas and ovarian cancers (Cosaert and Quoix, 2002; Hao et al., 2006; Pectasides et al., 2008; Muggia, 2009 ). In particular, testicular cancers are highly responsive to cisplatin treatment and this chemotherapeutic agent efficiently eradicates early stage testicular tumors (Kollmannsberger et al., 2006) . Furthermore, the development of cisplatin analogues carboplatin and oxaliplatin has extended the range of tumors treatable with platinum compounds. Carboplatin has replaced cisplatin in some treatment regimes as this drug produces less deleterious side effects, such as nephrotoxicity and neurotoxicity, while showing similar cytotoxic potency to cisplatin. Oxaliplatin has shown efficacy against cisplatin-resistant tumors, and consequently, this agent has been approved for the treatment of colorectal cancers (Kim and Erlichman, 2007) . Previous studies have shown that ERK activation induced by growth factors, cytokines or oncogenic activators of MAPK in tumor cells promotes cell survival (Xia et al., 1995; Bonni et al., 1999; Sheridan et al., 2008) . ERK inhibits apoptosis under the latter conditions, partly through inactivation of the BH3-only proteins Bim and Bad (Bonni et al., 1999; Ley et al., 2003; Sheridan et al., 2008; O'Reilly et al., 2009) . However, here we show that hyperactivation of ERK in 
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C Sheridan et al response to cisplatin promotes cell death, suggesting that ERK may positively or negatively regulate apoptosis, depending on the context. Activation of ERK has been linked to cisplatin-mediated apoptosis, however the molecular mechanism was obscure (Wang et al., 2000; Schweyer et al., 2004; Amran et al., 2005) . In this study, cisplatin-induced ERK activation was found to be essential for Noxa upregulation following cisplatin treatment and inhibition of the MAPK pathway dramatically abrogated platinum-induced Noxa expression as well as apoptosis. ERK kinase controls a battery of transcription factors and recent studies indicate that hundreds of proteins are under ERK-dependent control (Schulze et al., 2004; von Kriegsheim et al., 2009) . Preliminary knockdown studies in our laboratory have ruled out a requirement for the ERK-regulated transcription factors Myc, Elk1, Fos, Jun, ATF3, ATF4, Fra1 and Sap1a in cisplatin-induced regulation of the Noxa promoter (Supplementary Figure  1) . Thus, at present it remains unclear precisely how ERK activation leads to transcriptional upregulation of Noxa, although this is an issue we are currently exploring.
Because Mcl-1 is one of the highest affinity interaction partners for Noxa within the Bcl-2 family, our data suggest that Mcl-1 expression levels may critically influence responsiveness to platinum compounds. Consistent with this, transient overexpression of Mcl-1 greatly increased resistance to cisplatin treatment. Furthermore, we also found that ablation of endogenous Mcl-1 sensitized cells to cisplatin-induced apoptosis. Thus, combination therapy with platinum compounds and Noxa-like BH3 mimetics, such as Obatoclax (GX15-070; Zhai et al., 2006; Nguyen et al., 2007; Schimmer et al., 2008) , which are capable of inhibiting Mcl-1, may improve the efficacy of platinum agents in the treatment of human cancers.
Materials and methods

Reagents
The following antibodies were used: anti-Noxa, anti-Bim and antiRas (Merck Bioscience, Nottingham, UK); anti-Bad, anti-ERK, anti-phospho-ERK and anti-cleaved caspase-3 (Cell Signaling Technology, Hertfordshire, UK); anti-Bid, anti-Mcl-1, anti-Bcl-xL and anti-Bcl-2 (BD Biosciences, Oxford, UK); anti-Actin and anti-a-Tubulin (MP Biomedicals, Illkirch, France); anti-B-Raf and anti-Bax (Santa Cruz Biotechnology, Heidelberg, Germany); anti-Bak (Milipore, Whatford, UK); anti-Puma (Prosci, Nottingham, UK) and anti-Flag (Sigma, Dublin, Ireland). The following chemicals were used: actinomycin D, daunorubicin, cisplatin, cycloheximide and oxaliplatin (Sigma); MG132 and carboplatin (Merck Bioscience); U0126, PD98059 and ERK Inhibitor peptide II (Cell Signaling Technology). Unless otherwise indicated, all other reagents were purchased from Sigma.
Cell lines and plasmids
HeLa and HL-60 cells were cultured in RPMI supplemented with 5% fetal calf serum, 2 mM L-glutamine. SK-MEL-3 and H460 cells were cultured in RPMI supplemented with 10% fetal calf serum, 2 mM L-glutamine. HT29 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 2 mM L-glutamine. The following plasmids were used: pEF-RasN17, pcDNA3-RasV12, pEFm-B-RafWT, pEFm-B-RafV600E, pcDNA3-Flag-CREB, pCDNA3-FlagMcl-1, pRetroSuper-Noxa shRNA, pRetroSuper-Mcl-1 shRNA, pMKO-Bim shRNA, pMKO-Bad shRNA, pFUGWBax shRNA and pFUGW-Bak shRNA, pENTR-ATF4 shRNA, pSUPER-Fra1 shRNA, pSUPER-ATF3 shRNA 1 and pSUPER-ATF3 shRNA 2.
Apoptosis assays
Cells were plated at 1 Â 10 5 cells per well (1 Â 10 6 cells per well for HL-60 cells) in six-well plates and 24 h later were treated with proapoptotic drugs for a further 12-24 h before enumeration of apoptosis based on cell morphology (cell rounding, detachment from the plate, nuclear condensation and presence of apoptotic bodies). A minimum of 300 cells were counted in each treatment. Each assay was repeated three times. Where appropriate, cell lysates were prepared using SDS-polyacrylamide gel electrophoresis (PAGE) loading buffer and protein expression was examined by western immunoblotting. 
RNA interference
Transfection and western immunoblotting
To examine the effect of oncogenic Ras and B-Raf on BH3-only Bcl-2 family members, we plated HeLa cells at 1 Â 10 6 cells per 10 cm dish. After 24 h, cells were transfected with plasmids using GeneJuice (Merck Biosciences) as per the manufacturer's instructions. After 24 h, cell lysates were prepared using SDS-PAGE loading buffer and were electrophoresed on 12-13.5% SDS-PAGE. Protein expression was examined by western immunoblotting.
Immunoprecipitation analysis
HeLa cells plated at 0.75 Â 10 6 cells per 10 cm dish were transfected with 5 mg Flag-CREB and Flag-Mcl-1 plasmids using GeneJuice as per the manufacturer's instructions. After 48 h, cells were treated with cisplatin (100 mM) for 8 h and lysates were prepared using IP lysis buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 1% NP-40). The clarified supernatants were incubated with 1 mg anti-Flag antibody and 50 ml protein A/G-agarose (Santa Cruz Biotechnology) overnight at 4 1C. The beads were extensively washed in IP lysis buffer containing 0.1% NP-40 and samples were electrophoresed on SDS-PAGE, followed by immunoblotting.
Microscopy and image analysis
Microscopic images were acquired on an Olympus IX71 with LCPLanF1 Â 20 objective lens (Olympus, Hamburg, Germany). The camera used to acquire microscopic images was an Olympus U-CMAD3. Images were acquired at room temperature in RPMI containing 5% fetal calf serum, typically with Â 200 magnification, using Analysis software and were processed using Adobe Photoshop and Adobe InDesign. For the images shown in Figures 2d and 7c , a Canon PowerShot G9 camera (Cannon, Dublin, Ireland) was used. All images were processed using Adobe Photoshop and Adobe InDesign.
